Open Access

REVIEW

The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy

Xue Cui^1,2, Min Peng², Honglei Chen^1,*

1 Department of Pathology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China
2 Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China

* Corresponding Author: Honglei Chen. Email:

(This article belongs to the Special Issue: Cancer Immunotherapy)

Oncologie 2022, 24(4), 665-678. https://doi.org/10.32604/oncologie.2022.023641

Received 07 May 2022; Accepted 07 November 2022; Issue published 31 December 2022

Abstract

The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and anti-infection immunity. Immune combination therapy with LAG-3 is a hot topic, but its limitations in clinical application are also evident. This review briefly describes the molecular structure, biological functions of LAG-3 in the immune cells and cancer cells and prognosis significance, and then an overview of relevant ongoing clinical trials.

---

Keywords

---